EUVIMEDEUVIMED entdecken
Open Access

Esophageal cancer cell-derived small extracellular vesicles decrease circulating Tfh/Tfr via sEV-PDL1 to promote immunosuppression

Zijie Li, Yuehua Zhang, He Hao, Lu Chen, Tingting Lv, Xiaokuan Zhang, Yuying Qi, Zhiyu Wang

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03561-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Zijie Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Medical University, Shijiazhuang, 050011, Hebei, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Extracellular Vesicles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Basic Research Cooperation Project of Beijing, Tianjin, Hebei from the Natural Science Foundation of Hebei (H2020206649), Tianjin (20JCZXJC00070), and Beij…, The key Research and Development Program of Hebei Province..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal cancer (EC) is a deadly malignancy. Small extracellular vesicles (sEVs) with programmed death ligand 1 (sEV-PDL1) induce immune escape to promote tumor progression. Furthermore, the imbalance between circulating follicular helper T (Tfh) and circulating follicular regulatory T (Tfr) cells is related to the progression of many malignant tumors. However, the role of the EC-derived sEV-PDL1 in circulating Tfh/Tfr is unknown. Circulating Tfh and Tfr cells were detected by flow cytometry. sEVs were isolated through differential centrifugation and cultured for cell expansion assays. Naïve CD4+ T cells were isolated, stimulated, and cultured with sEVs to evaluate the frequencies, phenotypes, and functions of Tfh and Tfr cells. The proportion of circulating Tfh in patients with EC was lower than that in healthy donors (HDs), whereas that of circulating Tfr was higher. The EC group showed significantly lower circulating Tfh/Tfr and a higher level of sEV-PDL1 than HDs. Notably, sEV-PDL1 was negatively correlated with circulating Tfh/Tfr in the EC group. In vitro assays, sEV-PDL1 inhibited Tfh expansion, enhanced the cytotoxic T lymphocyte-associated antigen 4+ (CTLA4+) Tfh cell percentage, decreased the levels of interleukin (IL)-21 and interferon-γ, and increased IL-10. sEV-PDL1 promoted the expansion and immunosuppressive functions of circulating Tfr; the increased percentages of CTLA4+ Tfr and inducible T cell co-stimulator+ Tfr were accompanied with high IL-10. However, applying an anti-PDL1 antibody significantly reversed this. Our results suggest a novel mechanism of sEV-PDL1-mediated immunosuppression in EC. Inhibiting sEV-PDL1 to restore circulating Tfh/Tfr balance provides a novel therapeutic approach for EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsExtracellular VesiclesHumansT-Lymphocytes, Helper-InducerT Follicular Helper CellsInterleukin-10CTLA-4 AntigenB7-H1 AntigenT-Lymphocytes, RegulatoryImmunosuppression Therapy

Stichwörter der Autor:innen

Esophageal cancerFollicular helper T cellsFollicular regulatory T cellsImmunosuppressionsEV-PDL1

Substanzen

Interleukin-10CTLA-4 AntigenB7-H1 Antigen

Autor:innen und Institutionen

  • Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
  • Department of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050010, Hebei, China.
  • Department of Internal Medicine, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, Henan, China.
  • Hebei Medical University, Shijiazhuang, 050011, Hebei, China. drwangzhiyu@hebmu.edu.cn.

Förderung

  • The Basic Research Cooperation Project of Beijing, Tianjin, Hebei from the Natural Science Foundation of Hebei (H2020206649), Tianjin (20JCZXJC00070), and Beij…
  • The key Research and Development Program of Hebei Province.

Zitieren

APA

Li, Z., Zhang, Y., Hao, H., Chen, L., Lv, T., Zhang, X., Qi, Y., & Wang, Z. (2023). Esophageal cancer cell-derived small extracellular vesicles decrease circulating Tfh/Tfr via sEV-PDL1 to promote immunosuppression. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03561-w

Vancouver

Li Z, Zhang Y, Hao H, Chen L, Lv T, Zhang X, et al. Esophageal cancer cell-derived small extracellular vesicles decrease circulating Tfh/Tfr via sEV-PDL1 to promote immunosuppression. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03561-w

BibTeX
@article{Li2023,
  author = {Li, Zijie and Zhang, Yuehua and Hao, He and Chen, Lu and Lv, Tingting and Zhang, Xiaokuan and Qi, Yuying and Wang, Zhiyu},
  title = {Esophageal cancer cell-derived small extracellular vesicles decrease circulating Tfh/Tfr via sEV-PDL1 to promote immunosuppression},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03561-w}
}
Kostenlos starten →